OLD Category: signatures

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma

• Castaneda-Puglianini O, Chavez JC

Molecular subtyping of breast cancer intrinsic taxonomy with oligonucleotide microarray and NanoString nCounter

• Chen YJ, Huang CS, Phan NN, Lu TP, Liu CY, Huang CJ, Chiu JH, Tseng LM, Huang CC

Genome-wide microRNA expression profiling of molecular subgroups of peripheral T-cell lymphoma

• Lone W, Bouska A, Sharma S...Vose JM, Chan WC, Iqbal J

Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target

• Gould C, Lickiss J, Kankanige Y...Neeson PJ, Westerman D, Blombery P

Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

• Cascone T, Weissferdt A, Godoy MCB...Vaporciyan AA, Heymach JV, Sepesi B

Tear Lipocalin and Lipocalin-Interacting Membrane Receptor

• Glasgow BJ

Spatially Resolved Immunometabolism to Understand Infectious Disease Progression

• Tans R, Dey S, Dey NS, Calder G, O’Toole P, Kaye PM, Heeren RMA

Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues

• Fan TWM, Higashi RM, Song H...He D, Wang C, Lane AN

PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma

• Hußtegge M, Hoang NA, Rebstock J...Lordick F, Kallendrusch S, Körfer J

Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection

• Yatim N, Boussier J, Tetu P...Terrier B, Duffy D, Lebbé C

A 4-Gene Signature Associated With Recurrence in Low- and Intermediate-Risk Endometrial Cancer

• de Andrade DAP, da Silva LS, Laus AC...Carvalho JP, Reis RM, dos Reis R

New Technologies to Image Tumors

• McNamara G, Lucas J, Beeler JF, Basavanhally A, Lee G, Hedvat CV, Baxi VA, Locke D, Borowsky A, Levenson R